阿来替尼对克唑替尼耐药ALK阳性非小细胞肺癌中枢神经系统转移的疗效:RECIST 1.1与RANO-HGG标准比较
汇总两项II期研究,评估阿来替尼600mg每日两次口服在克唑替尼经治ALK阳性非小细胞肺癌患者中的中枢神经系统疗效。RECIST 1.1评估的中枢神经系统客观缓解率为64.0%,RANO-HGG为53.5%,中位缓解持续时间分别为10.8个月和11.1个月,两种标准一致率为92%。
要点
- RECIST 1.1评估中枢神经系统客观缓解率64.0%,RANO-HGG为53.5%
- 中位缓解持续时间RECIST 10.8个月,RANO-HGG 11.1个月
- 两种标准评估一致率92%,仅3例(8%)进展判定不一致
核心结论
- 阿来替尼在克唑替尼经治的ALK阳性非小细胞肺癌患者中枢神经系统转移中显示出有前景的疗效,无论采用何种评估标准。
研究设计与样本
- 汇总两项II期研究(NP28761北美研究、NP28673全球研究),纳入既往接受克唑替尼治疗的≥18岁ALK阳性非小细胞肺癌患者,所有患者接受阿来替尼600mg口服每日两次并有基线中枢神经系统影像,由独立审查委员会评估中枢神经系统缓解。
主要发现
- RECIST 1.1可测量中枢神经系统病灶患者50例,RANO-HGG可测量患者43例。
- 中枢神经系统客观缓解率RECIST 1.1为64.0%(95%CI 49.2-77.1;11例中枢神经系统完全缓解),RANO-HGG为53.5%(95%CI 37.7-68.8;8例完全缓解)。
- 中位缓解持续时间RECIST 1.1为10.8个月,RANO-HGG为11.1个月。
- 两种标准均可测量中枢神经系统病灶的39例患者中,仅3例(8%)按一种标准判定进展而另一种未判定,一致率92%。
关键数值与推荐
- RECIST 1.1中枢神经系统客观缓解率64.0%(95%CI 49.2-77.1),完全缓解11例。
- RANO-HGG中枢神经系统客观缓解率53.5%(95%CI 37.7-68.8),完全缓解8例。
- RECIST 1.1中位缓解持续时间10.8个月,RANO-HGG为11.1个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Central nervous system (CNS) progression is common in patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving crizotinib. Next-generation ALK inhibitors have shown activity against CNS metastases, but accurate assessment of response and progression is vital. Data from two phase II studies in crizotinib-refractory ALK+ NSCLC were pooled to examine the CNS efficacy of alectinib, a CNS-active ALK inhibitor, using Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) and Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG) criteria. METHODS: Both studies enrolled patients aged ≥18 years who had previously received crizotinib. NP28761 was conducted in North America and NP28673 was a global study. All patients received 600 mg oral alectinib twice daily and had baseline CNS imaging. CNS response for those with baseline CNS metastases was determined by an independent review committee. RESULTS: Baseline measurable CNS disease was identified in 50 patients by RECIST and 43 by RANO-HGG. CNS objective response rate was 64.0% by RECIST (95% confidence interval [CI]: 49.2-77.1; 11 CNS complete responses [CCRs]) and 53.5% by RANO-HGG (95% CI: 37.7-68.8; eight CCRs). CNS responses were durable, with consistent estimates of median duration of 10.8 months with RECIST and 11.1 months with RANO-HGG. Of the 39 patients with measurable CNS disease by both RECIST and RANO-HGG, only three (8%) had CNS progression according to one criteria but not the other (92% concordance rate). CONCLUSION: Alectinib demonstrated promising efficacy in the CNS for ALK+ NSCLC patients pretreated with crizotinib, regardless of the assessment criteria used.
引用
- Gandhi L, Ou SI, Shaw AT, et al. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017. PMID: 28646771. doi:10.1016/j.ejca.2017.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。